Angiotensin-Converting Enzyme 2 (G8790A) Gene Polymorphism as a Risk Factor for COVID-19 in Egyptian Children and Adolescents.

Objective: Recently, angiotensin-converting enzyme 2 (ACE2) gene has emerged as a potential candidate gene for susceptibility to SARS-CoV-2 infection. We investigated whether ACE2 G8790A (rs2285666) polymorphism could be a genetic marker for susceptibility to COVID-19 and disease severity in Egyptian children and adolescents.

Methods: This was a prospective case-control study included 580 cases diagnosed with COVID-19, and 580 matched control children and adolescents.

"Polyethylene Terephthalate Nanoplastics Caused Hepatotoxicity in Mice Can be Prevented by Betaine: Molecular and Immunohistochemical Insights".

Polyethylene terephthalate nanoplastics (PET-NPs) are one of the most frequently distributed nanoplastics in daily life. Betaine is thought to be a promising hepatoprotective agent. The current investigation focused on whether orally administered PET-NPs caused hepatotoxicity and ameliorative effect of betaine.

FERDCNN: an efficient method for facial expression recognition through deep convolutional neural networks.

Facial expression recognition (FER) has caught the research community's attention recently because it can affect many real-life applications. Multiple studies have focused on automatic FER, most of which use a machine learning methodology, FER has continued to be a difficult and exciting issue in computer vision. Deep learning has recently drawn increased attention as a solution to several practical issues, including facial expression recognition.

A Comprehensive Review of Mxene-Based Emerging Materials for Energy Storage Applications and Future Perspectives.

MXenes is a rapidly emerging class of two-dimensional (2D) materials. It exhibits unique properties that make it suitable for a wide range of applications. This review provides a comprehensive overview of the synthesis and processing techniques for MXenes including both bottom-up and top-down approaches.

Safety, tolerability, and immunogenicity of PIKA-adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine in healthy adults: an open-label randomized phase I clinical trial.

Purpose: This phase I study aimed to assess the safety, tolerability, and immunogenicity of the PIKA-adjuvanted recombinant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein subunit vaccine in healthy adults aged 18 years and older.

Materials And Methods: This is a phase I, open-label, dose-escalation study at three dose levels (5 µg, 10 µg, and 20 µg) of the PIKA coronavirus disease 2019 (COVID-19) vaccine administered intramuscularly. The three vaccine arms are (A) subjects who have never received any COVID-19 vaccination or have had COVID-19 infection for >6 months prior to enrolment; (B1) subjects whose COVID-19 primary vaccination series was completed with an inactivated COVID-19 vaccine; and (B2) subjects whose primary series was completed with messenger RNA COVID-19 vaccine.